An acenocoumarol dosing algorithm using clinical and pharmacogenetic data in Spanish patients with thromboembolic disease

PLoS ONE

Volumn 7, Issue 7, 2012, Pages

  Borobia, Alberto M ^a   Lubomirov, Rubin ^b   Ramírez, Elena ^a   Lorenzo, Alicia ^a   Campos, Armando ^a   Muñoz Romo, Raul ^a   Fernández Capitán, Carmen ^a   Frías, Jesús ^a   Carcas, Antonio J ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^b UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ACENOCOUMAROL; APOLIPOPROTEIN E; CYTOCHROME P450; CYTOCHROME P450 2C; CYTOCHROME P450 2C9; CYTOCHROME P450 4F2; UNCLASSIFIED DRUG;

AGED; ALGORITHM; ANALYTICAL ERROR; APOE GENE; ARTICLE; BODY MASS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYP2C9 GENE; CYP4F2 GENE; DOSE RESPONSE; FEMALE; GENE; GENETIC ASSOCIATION; GENETIC VARIABILITY; HUMAN; INTERNATIONAL NORMALIZED RATIO; MAJOR CLINICAL STUDY; MALE; PHARMACOGENETICS; PROCESS DEVELOPMENT; SPAIN; THROMBOEMBOLISM; VKORC1 GENE;

ACENOCOUMAROL; AGED; ALGORITHMS; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; MODELS, BIOLOGICAL; PHARMACOGENETICS; SPAIN; THROMBOEMBOLISM;

EID: 84864103206     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0041360     Document Type: Article

References (39)

1. Stehle S, Kirchheiner J, Lazar A, Fuhr U, (2008) Pharmacogenetics of oral anticoagulants: a basis for dose individualization. Clin Pharmacokinet 47(9): 565-94.
2. Takahashi H, Wilkinson GR, Padrini R, Echizen H, (2004) CYP2C9 and oral anticoagulation therapy with acenocoumarol and warfarin: similarities yet differences. Clin Pharmacol Ther 75: 376-380.
3. Schalekamp T, Brassé BP, Roijers JFM, Chahid Y, van Geest-Daalderop JHH, et al. (2006) VKORC1 and CYP2C9 genotypes and acenocoumarol anticoagulation status: Interaction between both genotypes affects overanticoagulation. Clin Pharmacol Ther 80(1): 13-22.
4. Martindale: The Complete Drug Reference. [online] London: Pharmaceutical Press. Accessed Available:http://www.medicinescomplete.com. 19 January (2012)
5. Spreafico M, Lodigiani C, van Leeuwen Y, Pizzotti D, Rota LL, et al. (2008) Effects of CYP2C9 and VKORC1 on INR variations and dose requirements during initial phase of anticoagulant therapy. Pharmacogenomics 9(9): 1237-50.
6. Teichert M, van Schaik RH, Hofman A, Uitterlinden AG, de Smet PA, et al. (2009) Genotypes associated with reduced activity of VKORC1 and CYP2C9 and their modification of acenocoumarol anticoagulation during the initial treatment period. Clin Pharmacol Ther 85(4): 379-86.
7. Pérez-Andreu V, Roldán V, Antón AI, García-Barberá N, Corral J, et al. (2009) Pharmacogenetic relevance of CYP4F2 V433M polymorphism on acenocoumarol therapy. Blood 113(20): 4977-9.
8. Caldwell MD, Awad T, Johnson JA, Gage BF, Falkowski M, et al. (2008) CYP4F2 genetic variant alters required warfarin dose. Blood 111(8): 4106-12.
9. Teichert M, Eijgelsheim M, Rivadeneira F, Uitterlinden AG, van Schaik RH, et al. (2009) A genome-wide association study of acenocoumarol maintenance dosage. Hum Mol Genet 18(19): 3758-68.
10. Pérez-Andreu V, Roldán V, López-Fernández MF, Antón AI, Alberca I, et al. (2010) Pharmacogenetics of acenocoumarol in patientswith extreme doserequirements. J Thromb Haemost 8(5): 1012-7.
11. Visser LE, Trienekens PH, De Smet PA, Vulto AG, Hofman A, et al. (2005) Patients with an APOE epsilon4 allele require lower doses of coumarin anticoagulants. Pharmacogenet Genomics 15(2): 69-74.
12. Cadamuro J, Dieplinger B, Felder T, Kedenko I, Mueller T, et al. (2010) Genetic determinants of acenocoumarol and phenprocoumon maintenance dose requirements. Eur J Clin Pharmacol 66(3): 253-60.
13. Hofman A, Grobbee DE, de Jong PT, van den Ouweland FA, (1991) Determinants of disease and disability in the elderly: the Rotterdam Elderly Study. Eur J Epidemiol 7(4): 403-22.
14. Palareti G, Leali N, Coccheri S, Poggi M, Manotti C, et al. (1996) Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Italian Study on Complications of Oral Anticoagulant Therapy. Lancet 348(9025): 423-8.
15. van der Meer FJ, Rosendaal FR, Vandenbroucke JP, Briët E, (1993) Bleeding complications in oral anticoagulant therapy. An analysis of risk factors. Arch Intern Med 153(13): 1557-62.
16. Anderson JL, Horne BD, Stevens SM, Grove AS, Barton S, et al. (2007) Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation. Circulation 116(22): 2563-70.
17. Millican EA, Lenzini PA, Milligan PE, Grosso L, Eby C, et al. (2007) Genetic-based dosing in orthopedic patients beginning warfarin therapy. Blood 110(5): 1511-5.
18. Sconce EA, Khan TI, Wynne HA, Avery P, Monkhouse L, et al. (2005) The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood 106(7): 2329-33.
19. Wu AH, (2007) Use of genetic and nongenetic factors in warfarin dosing algorithms. Pharmacogenomics 8(7): 851-61.
20. Caldwell MD, Berg RL, Zhang KQ, Glurich I, Schmelzer JR, et al. (2007) Evaluation of genetic factors for warfarin dose prediction. Clin Med Res 5(1): 8-16.
21. Klein TE, Altman RB, Eriksson N, Gage BF, Kimmel SE, et al. (2009) Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med 360(8): 753-64.
22. Meijer K, Kim YK, Carter D, Schulman S, (2011) A prospective study of an aggressive warfarin dosing algorithm to reach and maintain INR 2 to 3 after heart valve surgery. Thromb Haemost 105(2): 232-8.
23. Zambon CF, Pengo V, Padrini R, Basso D, Schiavon S, et al. (2011) VKORC1, CYP2C9 and CYP4F2 genetic-based algorithm for warfarin dosing: an Italian retrospective study. Pharmacogenomics 12(1): 15-25.
24. Moreau C, Pautas E, Gouin-Thibault I, Golmard JL, Mahé I, et al. (2011) Predicting the warfarin maintenance dose in elderly inpatients at treatment initiation: accuracy of dosing algorithms incorporating or not VKORC1/CYP2C9 genotypes. J Thromb Haemost 9(4): 711-718.
25. Lenzini P, Wadelius M, Kimmel S, Anderson JL, Jorgensen AL, et al. (2010) Integration of genetic, clinical, and INR data to refine warfarin dosing. Clin Pharmacol Ther 87(5): 572-8.
26. Verde Z, Ruiz JR, Santiago C, Valle B, Bandrés F, et al. (2010) A novel, single algorithm approach to predict acenocoumarol dose based on CYP2C9 and VKORC1 allele variants. PLoS One 5(6): e11210.
27. Rianne MF, van Schie RM, Wessels JA, le Cessie S, de Boer A, et al. (2011) Loading and maintenance dose algorithms for phenprocoumon and acenocoumarol using patient characteristics and pharmacogenetic data. Eur Heart J 32(15): 1909-17.
28. vanSchie RM, Wadelius MI, Kamali F, Daly AK, Manolopoulos VG, et al. (2009) Genotype-guided dosing of coumarin derivatives: the European pharmacogenetics of anticoagulant therapy (EU-PACT) trial design. Pharmacogenomics 10(10): 1687-95.
29. Sheiner LB, Beal SL, (1981) Some suggestions for measuring predictive performance. Journal Pharmacokinet Biopharm 9(4): 503-512.
30. Cook RJ, Sackett DL, (1995) The number needed to treat: a clinically useful measure of treatment effect. BMJ 310(6977): 452-4.
31. Caraco Y, Blotnick S, Muszkat M, (2008) CYP2C9 genotype-guided warfarin prescribing enhances the efficacy and safety of anticoagulation: a prospective randomized controlled study. Clin Pharmacol Ther 83(3): 460-70.
32. Gadisseur AP, van der Meer FJ, Adriaansen HJ, Fihn SD, Rosendaal FR, (2002) Therapeutic quality control of oral anticoagulant therapy comparing the short-acting acenocoumarol and the long-acting phenprocoumon. British J Haematol 117: 940-946.
33. Landefeld CS, Goldman L, (1989) Major bleeding in outpatients treated with warfarin: incidence and prediction by factors known at the start of outpatient therapy. Am J Med 87(2): 144-52.
34. Hirsh J, Fuster V, Ansell J, Halperin JL, (2003) American Heart Association/American College of Cardiology Foundation guide to warfarin therapy. Circulation 107: 1692-1711.
35. Ansell J, Hirsh J, Dalen J, Bussey H, Anderson D, et al. (2001) Managing oral anticoagulant therapy. Chest 119(1 Suppl) pp. 22S-38S.
36. Guijarro R, Montes J, Sanromán C, Monreal M, (2008) Venous thromboembolism in Spain. Comparison between an administrative database and the RIETE registry. Eur J Intern Med 19(6): 443-6.
37. Sagreiya H, Berube C, Wen A, Ramakrishnan R, Mir A, et al. (2010) Extending and evaluating a warfarin dosing algorithm that includes CYP4F2 and pooled rare variants of CYP2C9. Pharmacogenet Genomics 20(7): 407-13.
38. Cavallari LH, Butler C, Langaee TY, Wardak N, Patel SR, et al. (2011) Association of apolipoprotein E genotype with duration of time to achieve a stable warfarin dose in African-American patients. Pharmacotherapy 31(8): 785-92.
39. Rathore SS, Agarwal SK, Pande S, Singh SK, Mittal T, et al. (2012) Therapeutic Dosing of Acenocoumarol: Proposal of a Population Specific Pharmacogenetic Dosing Algorithm and Its Validation in North Indians. PLoS ONE 7(5): e37844.